| Catalogue number: | PA 01 3630000 | 
| Chemical name: | Asciminib | 
| CAS Number: | 1492952-76-7 | 
| Category: | metabolites,pharmaceutical standards,intermediates,Fine Chemicals | 
| Synonyms: | (R)-N-(4-(Chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-3-yl)nicotinamide; N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxy-1-pyrrolidinyl]-5-(1H-pyrazol-3-yl)-3-pyridinecarboxamide; N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-3-yl)pyridine-3-carboxamide; Scemblix; | 
| Molecular form: | C20H18ClF2N5O3 | 
| Appearance: | NA | 
| Mol. Weight: | 449.84 | 
| Storage: | 2-8°C Refrigerator | 
| Shipping Conditions: | Ambient | 
| Applications: | Asciminib is an inhibitor of ABL/BCR-ABL1 tyrosine kinase for the treatment of patients with Philadelphia chromosome-positive CML, including those with the T315I mutation.Asciminib is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein6 which serves as a driver of CML proliferation in most patients with the disease.8 It has also shown benefit in Ph+ CML with the T315I mutation, which produces a mutant BCR-ABL1 which is typically treatment-resistant as compared to wild-type BCR-ABL1. | 
Asciminib
Related Products
Search by Keywords – Buy 1492952-76-7 | Purchase 1492952-76-7 | Order 1492952-76-7 | Enquire 1492952-76-7 | Price of 1492952-76-7 | 1492952-76-7 Cost | 1492952-76-7 Supplier | 1492952-76-7 Distributor | 1492952-76-7 Manufacturer | 1492952-76-7 Exporter


 
		
			 
		 
		     
	
		 
		 
		 
		 
		 
		 
		 
		 
 
 
